Figure 5: Changes in CD4+CD25+CD127- Treg subsets according to CD49d expression.
(A) Changes in the percentage of CD25+CD127- and CD25+CD127-CD49d- Tregs during treatment in the DC-MCy-IL2 trial, at baseline and at time of the 4th and the 6th vaccine.
(B) Changes in the percentage of CD25+CD127- and CD25+CD127-CD49d- Tregs during treatment in the DC-MCy trial, at baseline and at time of the 4th and the 6th.
(C) Changes in the number of CD25+CD127- and CD25+CD127-CD49d- Tregs during treatment in the DC-MCy-IL2 trial and in the DC-MCy trial, at baseline and at time of the 4th and the 6th vaccine.
(D) Functional properties of Treg subsets: For analysis of inhibitory capacity of different Treg cell subsets, the CD25+CD127- (fraction 1), the CD25+CD127-CD49d- (fraction 2), the CD25+CD127-CD49d+ (fraction 3) or the CD25-CD127+ (control cells)(fraction 4) T cells were added to anti-CD3 stimulated autologous PBMCs from a buffy coat in a ratio of 1:1 (Tregs:responder cells). The cultures were incubated for 5 days and the percentage of CD4 T cell proliferation was analysed. % inhibition of CD4 is depicted.